Compare Symbotic Inc (SYM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs GeneDx Holdings Corp — how do they compare? Symbotic Inc trades at $42.89 (market cap $5.46B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: Symbotic Inc is far larger — about 2.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Symbotic Inc for 23 Days and GeneDx Holdings Corp for 19 Days on average.
| SYM | WGS | |
|---|---|---|
Market Cap | $5.46B | $2.02B |
Volume | 1,965,805 | 734,640 |
Sector | Industrials | Health |
52-Week High | $87.30 | $167.51 |
52-Week Low | $38.22 | $34.51 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $3.72B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $42.73, down 1.34% today, with bearish technical signals dominating. The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains positive with 61% buy ratings and a $60.33 price target, representing 41% upside potential from current levels.
The outlook balances growth potential against execution risks. SYM's $22.5B backlog and expanding AI/robotics market position offer substantial upside, but customer concentration (85% Walmart revenue) and recent earnings misses create near-term uncertainty. Technical indicators suggest caution with bearish moving average signals, though oversold conditions may present entry opportunities for long-term investors.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
